Cargando…

Differential effects of dosing regimen on the safety and efficacy of dasatinib: retrospective exposure–response analysis of a Phase III study

PURPOSE: Dasatinib is a prototypic short half-life BCR-ABL1 tyrosine kinase inhibitor. The recommended dose of dasatinib for chronic myeloid leukemia in chronic phase was changed from 70 mg twice daily to 100 mg once daily following a Phase III dose-optimization study. To better understand the super...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Xiaoning, Roy, Amit, Hochhaus, Andreas, Kantarjian, Hagop M, Chen, Tai-Tsang, Shah, Neil P
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2013
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3684141/ https://www.ncbi.nlm.nih.gov/pubmed/23788844 http://dx.doi.org/10.2147/CPAA.S42796

Ejemplares similares

The development of dasatinib as a treatment for chronic myeloid leukemia (CML): from initial studies to application in newly diagnosed patients
por: Hochhaus, Andreas, et al.
Publicado: (2013)

Dasatinib in imatinib‐resistant or ‐intolerant chronic‐phase, chronic myeloid leukemia patients: 7‐year follow‐up of study CA180‐034
por: Shah, Neil P., et al.
Publicado: (2016)

Long-term efficacy and safety of dasatinib in patients with chronic myeloid leukemia in accelerated phase who are resistant to or intolerant of imatinib
por: Ottmann, Oliver, et al.
Publicado: (2018)

Long‐term bosutinib for chronic phase chronic myeloid leukemia after failure of imatinib plus dasatinib and/or nilotinib
por: Cortes, Jorge E., et al.
Publicado: (2016)

Lymphocytosis after treatment with dasatinib in chronic myeloid leukemia: Effects on response and toxicity
por: Schiffer, Charles A., et al.
Publicado: (2016)

Efficacy and safety of 3‐month dosing regimen of degarelix in Japanese subjects with prostate cancer: A phase III study
por: Ozono, Seiichiro, et al.
Publicado: (2018)

Efficacy and Tolerability after Unusually Low Doses of Dasatinib in Chronic Myeloid Leukemia Patients Intolerant to Standard-Dose Dasatinib Therapy
por: Serpa, Mariana, et al.
Publicado: (2010)

Efficacy and safety of various repeat treatment dosing regimens of rituximab in patients with active rheumatoid arthritis: results of a Phase III randomized study (MIRROR)
por: Rubbert-Roth, Andrea, et al.
Publicado: (2010)

Phase II, Open Label, Randomized Comparative Trial of Ondansetron Alone versus the Combination of Ondansetron and Aprepitant for the Prevention of Nausea and Vomiting in Patients with Hematologic Malignancies Receiving Regimens Containing High-Dose Cytarabine
por: Badar, Talha, et al.
Publicado: (2015)

Safety and Activity of the Combination of Ceritinib and Dasatinib in Osteosarcoma
por: Beck, Olaf, et al.
Publicado: (2020)

Incidence, outcomes, and risk factors of pleural effusion in patients receiving dasatinib therapy for Philadelphia chromosome-positive leukemia
por: Hughes, Timothy P., et al.
Publicado: (2019)

Dasatinib dose management for the treatment of chronic myeloid leukemia
por: Talpaz, Moshe, et al.
Publicado: (2018)

A Phase I Study of Dasatinib with Concurrent Chemoradiation for Stage III Non-Small Cell Lung Cancer
por: Khurshid, Humera, et al.
Publicado: (2012)

Quantitative prediction of long-term molecular response in TKI-treated CML – Lessons from an imatinib versus dasatinib comparison
por: Glauche, Ingmar, et al.
Publicado: (2018)

BCR-ABL1 mutation development during first-line treatment with dasatinib or imatinib for chronic myeloid leukemia in chronic phase
por: Hughes, T P, et al.
Publicado: (2015)

Characterization of the Relationship of Inotuzumab Ozogamicin Exposure With Efficacy and Safety End Points in Adults With Relapsed or Refractory Acute Lymphoblastic Leukemia
por: Chen, Joseph, et al.
Publicado: (2020)

Exposure–Response Relationships for Efficacy and Safety of Risankizumab in Phase II and III Trials in Psoriasis Patients
por: Khatri, Amit, et al.
Publicado: (2019)

Nilotinib in patients with systemic mastocytosis: analysis of the phase 2, open-label, single-arm nilotinib registration study
por: Hochhaus, Andreas, et al.
Publicado: (2015)

New dosing schedules of dasatinib for CML and adverse event management
por: Wong, Siu-Fun
Publicado: (2009)

Relationship between Dasatinib-induced Pulmonary Hypertension and Drug Dose
por: Kubota, Kana, et al.
Publicado: (2022)

A Dasatinib-Induced Chylothorax Persisting After the Discontinuation of Dasatinib
por: Bradt, Nicolas, et al.
Publicado: (2022)

Dasatinib-Induced Colitis with Rectal Sparing in a Patient with Chronic Myeloid Leukemia (Chronic Phase) on Dasatinib as an Upfront Therapy: Case Report
por: Maat, Zakaria, et al.
Publicado: (2021)

Simultaneous Modeling of Biomarker and Toxicity Response Predicted Optimal Regimen of Guadecitabine (SGI‐110) in Myeloid Malignancies
por: Xu, Cong, et al.
Publicado: (2017)

Dasatinib-Related Chylothorax
por: Huang, Yen-Min, et al.
Publicado: (2015)

DASATINIB-RELATED CHYLOTHORAX
por: Young, Katherine, et al.
Publicado: (2019)

Plasma concentrations of dasatinib have a clinical impact on the frequency of dasatinib dose reduction and interruption in chronic myeloid leukemia: an analysis of the DARIA 01 study
por: Mizuta, Shuichi, et al.
Publicado: (2018)

Core binding factor acute myelogenous leukemia-2021 treatment algorithm
por: Borthakur, Gautam, et al.
Publicado: (2021)

Relative safety profiles of high dose statin regimens
por: Escobar, Carlos, et al.
Publicado: (2008)

Low-dose Dasatinib Ameliorates Hypertrophic Cardiomyopathy in Noonan Syndrome with Multiple Lentigines
por: Yi, Jae-Sung, et al.
Publicado: (2021)

Safety of bosutinib versus imatinib in the phase 3 BELA trial in newly diagnosed chronic phase chronic myeloid leukemia
por: Gambacorti-Passerini, Carlo, et al.
Publicado: (2014)

Dasatinib-induced Nonspecific Interstitial Pneumonia That Developed 7 Years after the Initiation of Dasatinib
por: Takekoshi, Daisuke, et al.
Publicado: (2020)

Dose/Exposure‐Response Modeling to Support Dosing Recommendation for Phase III Development of Baricitinib in Patients with Rheumatoid Arthritis
por: Zhang, Xin, et al.
Publicado: (2017)

Integrated exposure–response analysis of efficacy and safety of lurbinectedin to support the dose regimen in small-cell lung cancer
por: Fernández-Teruel, Carlos, et al.
Publicado: (2021)

Post hoc analysis of the relationship between baseline white blood cell count and survival outcome in a randomized Phase III trial of decitabine in older patients with newly diagnosed acute myeloid leukemia
por: Arthur, Christopher, et al.
Publicado: (2015)

Structural effects of clinically observed mutations in JAK2 exons 13-15: comparison with V617F and exon 12 mutations
por: Lee, Tai-Sung, et al.
Publicado: (2009)

Dosing Regimen Prediction and Confirmation With Rivaroxaban for Thromboprophylaxis in Children After the Fontan Procedure: Insights From the Phase III UNIVERSE Study
por: Zhu, Peijuan, et al.
Publicado: (2022)

Phase I clinical trial of the Src inhibitor dasatinib with dacarbazine in metastatic melanoma
por: Algazi, A P, et al.
Publicado: (2012)

Haemorrhagic Colitis Caused by Dasatinib
por: Patodi, Nishant, et al.
Publicado: (2012)

Dasatinib-induced Pulmonary Hypertension
por: Tamura, Yudai, et al.
Publicado: (2022)

Phase III Non-inferiority Study Evaluating Efficacy and Safety of Low Dose Gemcitabine Compared to Standard Dose Gemcitabine With Platinum in Advanced Squamous Lung Cancer
por: Patil, Vijay, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_ssi2p2vqg4k5dtpfvc4d0gqnce